Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 2
Submit an article Journal homepage
38
Views
4
CrossRef citations to date
0
Altmetric
Review

Therapeutic potential of macrolide immunosuppressants in dermatology

Alexander M Marsland Konishi-MUSC Institute for Inflammation Research, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA. [email protected]
&
Christopher EM Griffiths Konishi-MUSC Institute for Inflammation Research, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA. [email protected]
Pages 125-137 | Published online: 02 Mar 2005

Bibliography

  • BRINKMANN V, KRISTOFIC C: Regulation by corticosteroids of Thl and Th2 cytokine production in human CD4+ effector T cells generated from CD45R0-and CD45RO±subsets. Innnunol. (1995) 155:3322–3328.
  • IRAKAM A, MISKOLCI V, VANCUROVA I, DAVIDSON D: Dose- related inhibition of proinflammatory cytokine release from neutrophils of the newborn by dexamethasone, betamethasone, and hydrocortisone. Biol. Neonate (2002) 82:89–95.
  • CRONSTEIN BN, KIMMEL SC, LEVIN RI, MARTINIUK F, WEISSMANN G: A mechanism for the anti-inflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Nati Acad. Sci. USA (1992) 89:9991–9995.
  • NARAY-FEJES-TOTH A, CORN WELL GG, GUYRE PM: Glucocorticoids inhibit IgE receptor expression on the human monocyte cell line U937. Immunology (1985) 56:359–366.
  • AMIN AR, VYAS P, ATTUR M et al.: The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc. Nati Acad. Sci.USA (1995) 92:7926–7930.
  • LEWIS GD, CAMPBELL WB, JOHNSON AR: Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology (1986) 119:62–69.
  • LEUNG DY, BLOOM JW: Update on glucocorticoid action and resistance.
  • •• J. Allergy Clin. Immunol. (2003) 111:3-22; quiz 23.
  • HILL CJ, ROSTENBERG A Jr: Adverse effects from topical steroids. Cutts (1978) 21:624–628.
  • COOK LJ, FREINKEL RK, ZUGERMAN C, LEVIN DL, RADTKE R: Iatrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria. J. Am. Acad. Dermatol. (1982) 6:1054–1060.
  • SCHACKE H, DOCKE WD, ASADULLAH K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Titer: (2002) 96:23–43.
  • CHARMAN CR, MORRIS AD, WILLIAMS HC: Topical corticosteroid phobia in patients with atopic eczema. Br. J. Dermatol. (2000) 142:931–936.
  • BARRY BW, WOODFORD R: Vasoconstrictor activities and bio-availabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications. Br. J. Dermatol. (1977) 97:555–560.
  • ROBERT C, KUPPER TS: Inflammatory skin diseases, T cells, and immune surveillance. N Engl. J. Med. (1999) 341:1817–1828.
  • ••Excellent background review article oninflammatory skin diseases.
  • BLAUVELT A, HWANG ST, UDEY MC: 11. Allergic and immunologic diseases of the skin. I Allergy Clin. Immunol. (2003) 111:S560–S570.
  • ••Another very interesting article oninflammatory skin diseases.
  • RICHARDS HL, FORTUNE DG, MAIN CJ, GRIFFITHS CE: Stigmatization and psoriasis. Br. J. Dermatol. (2003) 149:209–211.
  • DAVISON SC, ALLEN MH, MALLON E, BARKER JN: Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate versus chronic plaque psoriasis. Br. J. Dermatol (2001) 145:245–251.
  • GRIFFITHS CE: The immunological basis of psoriasis. J. Eur. Acad. Dermatol. Venereol. (2003) 17\(Suppl. 2):1–5.
  • GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:442–447.
  • OWEN CM, HARRISON PV: Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol. (2000) 25:195–197.
  • PRINZ J, BRAUN-FALCO 0, MEURER M et al.: Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet (1991) 338:320–321.
  • ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Clin. Invest. (1999) 103:1243–1252.
  • ELLIS CN, KRUEGER GG: Treatment ofchronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. J. Med. (2001) 345:248–255.
  • SCHLAAK JF, BUSLAU M, JOCHUM W et al.: T cells involved in psoriasis vulgaris belong to the Thl subset. Invest. Dermatol. (1994) 102:145–149.
  • DE JONG R, BEZEMER AC, ZOMERDIJK TP et al.: Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. .1 Immunol. (1996) 26:2067–2074.
  • GHORESCHI K, THOMAS P, BREIT S et al.: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. (2003) 9:40–46.
  • ASADULLAH K, STERRY W, STEPHANEK K et al.: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. Clin. Invest. (1998) 101:783–794.
  • TREPICCHIO WL, OZAWA M, WALTERS IB et al: Interleukin-11 therapy selectively downregulates Type I cytokine proinflammatory pathways in psoriasis lesions. I Clin. Invest. (1999) 104:1527–1537.
  • CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357:1842–1847.
  • BHUSHAN M, MCLAUGHLIN B, WEISS JB, GRIFFITHS CE: Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br. J. Dermatol (1999) 141:1054–1060.
  • SAUDER DN, DEKOVEN J, CHAMPAGNE P, CROTEAU D, DUPONT E: Neovastat (AE-941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis. Am. Acad. Dermatol. (2002) 47:535–541.
  • GIROLOMONI G, SEBASTIANI S, ALBANESI C, CAVANI A: T-cell subpopulations in the development of atopic and contact allergy. Can: Opin. Immunol. (2001) 13:733–737.
  • GRABBE S, SCHWARZ T: Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol. Today (1998) 19:37–44.
  • HIRATA T, FURIE BC, FURIE B: P-, E-,and L-selectin mediate migration of activated CD8+ T lymphocytes into inflamed skin. I Immunol. (2002) 169:4307–4313.
  • ELLIS CN, DRAKE LA, PRENDERGAST MM et al.: Cost of atopic dermatitis and eczema in the United States. I Am. Acad. Dermatol. (2002) 46:361–370.
  • COOKSON WO, MOFFATT MF: The genetics of atopic dermatitis. Curt: Opin. Allergy Clin. Immunol. (2002) 2:383–387.
  • LEUNG DY: Atopic dermatitis and the immune system: the role of superantigens and bacteria. I Am. Acad. Dermatol. (2001) 45:S13–16.
  • AKDIS M, TRAUTMANN A, KLUNKER S, BLASER K, AKDIS CA: Cytokine network and dysregulated apoptosis in atopic dermatitis. Acta Odontol. Scand. (2001) 59:178–182.
  • STEWART GE 2nd: Histopathology of chronic urticaria. Clin. Rev. Allergy Immunol. (2002) 23:195–200.
  • HIDE M, FRANCIS DM, GRATTAN CE et al.: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl. I Med. (1993) 328:1599–1604.
  • ••Evidence of the autoirnmune nature ofurticaria in some patients.
  • KIKUCHI Y, KAPLAN AP: A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. I Allergy Clin. Immunol. (2002) 109:114–118.
  • OKAYAMA Y, BENYON RC, LOWMAN MA, CHURCH MK: In vitroeffects of Hl-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy (1994) 49:246–253.
  • KAPLAN AP: Clinical practice. Chronic urticaria and angioedema. N Engl. I Med (2002) 346:175–179.
  • •Easy-to-digest background article on clinical aspects of urticaria.
  • ERBAGCI Z: The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. Allergy Clin. Immunol (2002) 110:484–488.
  • GRATTAN CE, O'DONNELL BE FRANCIS DM et al.: Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br. Dermatol (2000) 143:365–372.
  • FREYSCHMIDT-PAUL P, ZIEGLER A, McELWEE KJ et al:Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur. Dermatol. (2001) 11:405–409.
  • FERRANDO J, GRIMALT R: Partial response of severe alopecia areata to cyclosporine A. Dermatology (1999) 199:67–69.
  • MOCHIZUKI M: Immunotherapy for Behcet's disease. Int. Rev Immunol (1997) 14:49–66.
  • NUSSENBLATT RB, PALESTINE AG, CHAN CC, MOCHIZUKI M, YANCEY K: Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum. (1985) 28:671–679.
  • LYON CC, STAPLETON M, SMITH AJ et al.: Topical tacrolimus in the management of peristomal pyoderma gangrenosum., " Dermatolog. Treat. (2001) 12:13–17.
  • LYON CC, KIRBY B, GRIFFITHS CE: Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. Br. J. Dermatol (1999) 140:562–564.
  • SCHOFER H, BAUR S: Successful treatment of postoperative pyoderma gangrenosum with cyclosporin.j Eur: Acad. Dermatol Venereol (2002) 16:148–151.
  • MORRISON L, KRATOCHVIL FJ 3rd, GORIVIAN A: An open trial of topical tacrolimus for erosive oral lichen planus. J. Am. Acad. Dermatol (2002) 47:617–620.
  • MORTON SJ, POWELL RJ: Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) (2000) 39:865–869.
  • WALKER SL, KIRBY B, CHALMERS RJ:Use of 0.1% tacrolimus ointment in patients with various forms of lupus erythematosus. Eur. Dermatol (2002) 12:387-388; author reply 389.
  • ASSMANN T, BECKER-WEGERICH P, GREWE M, MEGAHED M, RUZICKA T: Tacrolimus ointment for the treatment of vulvar lichen sclerosus. I Am. Acad. Dermatol. (2003) 48:935–937.
  • ELAD S, OR R, RESNICK I, SHAPIRA MY: Topical tacrolimus-a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl. Int. (2003) 16(9):665–70.
  • MARSLAND AM, GRIFFITHS CE: The macrolide immunosuppressants in dermatology: mechanisms of action. Eur. Dermatol (2002) 12:618–622.
  • •Review article detailing the mechanisms of action of macrolides.
  • BUENO OF, BRANDT EB, ROTHENBERG ME, MOLKENTIN JD: Defective T cell development and function in calcineurin Ab-deficient mice. Proc. Nati Acad. Sci. USA (2002) 99:9398–9403.
  • SPERR WR, AGIS H, CZERWENKA K et al.: Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. Allergy Clin. Immunol (1996) 98:389–399.
  • •Evidence that calcineurin inhibitors may additionally exert their effects independently from their effects on T lymphocytes.
  • KUHNS DB, YOUNG HA, GALLIN EK, GALLIN JI: Ca2±-dependent production and release of IL-8 in human neutrophils. Immunol. (1998) 161:4332–4339.
  • BRAUN RK, FRANCHINI M, ERARD F et al.: Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. Eur: Immunol. (1993) 23:956–960.
  • HOLSCHERMANN H, RASCHER C, OELSCHLAGER C et al.: Opposite regulation of tissue factor expression by calcineurin in monocytes and endothelial cells. J. Immunol (2001) 166:7112–7120.
  • HAUK PJ, LEUNG DY: Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?I Allergy Clin. Immunol. (2001) 107:391–392.
  • ALVAREZ-ARROYO MV, YAGUE S, WENGER RM et al.: Cyclophilin- mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial growth factor. Circ. Res. (2002) 91:202–209.
  • KRUMMREI U, BAULIEU EE, CHAMBRAUD B: The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis. Proc. Nati Acad. Sci. USA (2003) 100:2444–2449.
  • ZUBERBIER T, CHONG SU, GRUNOW K et al: The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. I Allergy Gin. Immunol. (2001) 108:275–280.
  • SPERR WR, AGIS H, SEMPER H et al.: Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. Int. Arch. Allergy Immunol. (1997) 114:68–73.
  • KHANNA A, PLUMMER M, BROMBEREK C, BRESNAHAN B, HARIHARAN S: Expression of TGF-I3 and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int. (2002) 62:2257–2263.
  • BENNETT WM: The nephrotoxicity of immunosuppressive drugs. Clin. Nephrol (1995) 43\(Suppl. 1):53–57.
  • HOJO M, MORIMOTO T, MALUCCIO M et al.: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 397:530–534.
  • •Insight into tumour-promoting capabilities of cyclosporin.
  • RAUGHT B, GINGRAS AC, SONENBERG N: The target of rapamycin(TOR) proteins. Proc. Nati Acad. Sci. USA (2001) 98:7037–7044.
  • ABRAHAM RT: Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curi: Opin. Immunol (1998) 10:330–336.
  • REITAMO S, SPULS P, SASSOLAS B et al.: Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br. I Dermatol. (2001) 145:438–445.
  • JAVIER AF, BATA-CSORGO Z, ELLIS CN et al.: Rapamycin (sirolimus) 134 Expert Op/n. Investig. Drugs (2004) 13(2) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J. Clin. Invest. (1997) 99:2094–2099.
  • GUBA M, VON BREITENBUCH P, STEINBAUER M et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. (2002) 8:128–135.
  • HUANG S, HOUGHTON PJ: Targeting mTOR signaling for cancer therapy. Carr: Opin. Pharmacol (2003) 3:371–377.
  • SCHON MP, KRAHN T, SCHON M et al.: Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. (2002) 8:366–372.
  • CAMPANA C, REGAZZI MB, BUGGIA I, MOLINARO M: Clinically significant drug interactions with cyclosporin. An update. Clin. Pharmacokinet. (1996) 30:141–179.
  • BURKE JF, JR., PIRSCH JD, RAMOS EL et al.: Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl. J. Med. (1994) 331:358–363.
  • BOERS M, DIJKMANS BA, VAN RIJTHOVEN AW, GOEI THE HS, CATS A: Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. Rheumatol (1990) 17:38–42.
  • RUSH DN: Cyclosporine toxicity to organs other than the kidney. Clin. Biochem. (1991) 24:101–105.
  • MYERS BD, ROSS J, NEWTON L, LUETSCHER J, PERLROTH M: Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. (1984) 311:699–705.
  • PAUL CF, HO VC, McGEOWN C et al:Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol (2003) 120:211–216.
  • BATES WD, GRAY DW, DADA MA et al:Lymphoproliferative disorders in Oxford renal transplant recipients. j Clin. Pathol (2003) 56:439–446.
  • PIGATTO PD, CHIAPPINO G, BIGARDI A, MOZZANICA N, FINZI AF: Cyclosporin A for treatment of severe lichen planus. Br. J. Dermatol (1990) 122:121–123.
  • CURLEY RK, MacFARLANE AW, VICKERS CF: Pyoderma gangrenosum treated with cyclosporin A. Br. J. Dermatol (1985) 113:601–604.
  • DIAZ-LLOPIS M, CERVERA M, MENEZO JL: Cyclosporin A treatment of Behcet's disease: a long-term study. Can: Eye Res (1990) 9(Suppl.):17–23.
  • BASSO M, FILACI G, CUTOLO M et al: Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Ann. Ital. Med. Int. (2001) 16:233–239.
  • REITAMO S, ERKKO P, REMITZ A et at Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch. Dermatol (1993) 129:1273–1279.
  • OHTSUKI M, NAKAGAWA H, SUGAI J et al.: Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J. Dermatol (2003) 30:290–298.
  • THACI D, BRAUTIGAM M, KAUFMANN R et al: Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology (2002) 205:383–388.
  • CZECH W, BRAUTIGAM M, WEIDINGER G, SCHOPF E: A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J. Am. Acad. Dermatol (2000) 42:653–659.
  • LEBWOHL M, ELLIS C, GOTTLIEB A et al.: Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. I. Am. Acad. Dermatol (1998) 39:464–475.
  • EPSTEIN JB, TRUELOVE EL: Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial. Oral Surg. Oral Med. Oral Pathol Oral Radio]. Endod. (1996) 82:532–536.
  • ROTHBARD JB, GARLINGTON S, UN Q et al: Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. (2000) 6:1253–1257.
  • ECKSTEIN JW, FUNG J: A new class ofcyclosporin analogues for the treatment of asthma. Expert Opin. Investig. Drugs (2003) 12:647–653.
  • LAZAROVA T, CHEN JS, HAMANN B et al.: Synthesis and biological evaluation of novel cyclosporin a analogues: potential soft drugs for the treatment of autoimmune diseases. J. Med. Chem. (2003) 46:674–676.
  • ECKSTEIN JW, SONDERFAN A, WEXLER R et al.: Novel efficacious cyclosporine 'soft drugs' with reduced toxicity. Federation of Clinical Immunology Societies, Paris, France (2003) (Abstract).
  • ABEL MD, ASPESLET LJ, FREITAG DG et al.: I5ATX247: a novel calcineurin inhibitor. J. Heart Lung Transplant (2001) 20:161.
  • McALISTER VC: New immunosuppressants in clinical trial. Curr. Drug Targets Cardiovasc. Haematol Disord. (2002) 2:73–77.
  • •Review article that details novel irmrtunosuppressants used in transplantation medicine, some of which may be of interest in the dermatoses discussed in this review.
  • GOTO T, KINO T, HATANAKA H et al: FK 506 historical perspectives. Transplant Proc. (1991) 23:2713–2717.
  • HESSELINK DA, VAN SCHAIK RH, VAN DER HEIDEN IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol The]: (2003) 74:245–254.
  • SCHROER B, LOCKEY R: Oral tacrolimus for severe recalcitrant atopic eczema. I Allergy Clin. Immunol (2003) 111:1409–1410.
  • THE EUROPEAN FK 506 MULTICENTRE PSORIASIS STUDY GROUP: Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch. Dermatol (1996) 132:419–423.
  • KOGA T, YANO T, ICHIKAWA Y, OIZUMI K, MOCHIZUKI M: Pulmonary infiltrates recovered by FK506 in a patient with Behcet's disease. Chest (1993) 104:309–311.
  • JAIN AB, YEE LD, NALESNIK MA et al: Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 66:1193–1200.
  • •Of interest.
  • PALLER A, EICHENFIELD LF, LEUNG DY, STEWART D, APPELL M: A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. I Am. Acad. Dermatol (2001) 44:S47–S57.
  • HANIFIN JM, LING MR, LANGLEY R, BRENEMAN D, RAFAL E: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J. Am. Acad. Dermatol (2001) 44:S28–S38.
  • NGHIEM P, PEARSON G, LANGLEY RG: Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. Am. Acad. Dermatol (2002) 46:228–241.
  • SARIPALLI YV, GADZIA JE, BELSITO DV: Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis.' Am. Acad. Dermatol (2003) 49:477–482.
  • SCHUPPE HC, HOMEY B, ASSMANN T, MARTENS R, RUZICKA T: Topical tacrolimus for pyoderma gangrenosum. Lancet (1998) 351:832.
  • TANGHETTI EA: Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutts (2003) 71:158–162.
  • WALKER SL, KIRBY B, CHALMERS RJ: The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br. Dermatol (2002) 147:405–406.
  • MCELWEE KJ, RUSHTON DH, TRACHY R, OLIVER RF: Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br. Dermatol (1997) 137:491–497.
  • THIERS BH: Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch. Dermatol (2000) 136:124.
  • PARK SW, KIM JVV, WANG HY: Topical tacrolimus (FK506): treatment failure in four cases of alopecia universalis. Acta Berm. Venereol (2002) 82:387–388.
  • FREEMAN AK, LINOWSKI GJ, BRADY C et al.: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. Am. Acad. Dermatol (2003) 48:564–568.
  • REMITZ A, REITAMO S, ERKKO P, GRANLUND H, LAUERMA Al: Tacrolimus ointment improves psoriasis in a microplaque assay. Br. J. Dermatol (1999) 141:103–107.
  • REITAMO S, RISSANEN J, REMITZ A et al.: Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial.' Invest. Dermatol (1998) 111:396–398.
  • KAWASHIMA M, NAKAGAWA H, OHTSUKI M, TAMAKI K, ISHIBASHI Y: Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet (1996) 348:1240–1241.
  • NIWA Y, TERASHIMA T, SUMI H: Topical tacrolimus potentiates carcinogenesis in mouse skin and reduces the lymph node CD4/CD8 ratio. International Investigative Dermatology Miami Beach, FL, USA (2003) (Abstract).
  • ARAI T, KOUAMA Y, SUENAGA T, HONDA H: Ascomycin, an antifungal antibiotic. Antibiot. (Tokyo) (1962) 15:231–232.
  • HO VC, GUPTA A, KAUFMANN R et al.: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. Pediatr. (2003) 142:155–162.
  • WAHN U, BOS JD, GOODFIELD M et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 110:e2.
  • MEURER M, FOLSTER-HOLST R, WOZEL G et al.: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology (2002) 205:271–277.
  • GRAHAM-BROWN RA, GRASSBERGER M: Pimecrolimus: a review of pre-clinical and clinical data. Int. Gin. Pratt (2003) 57:319–327.
  • •Comprehensive review of data on pimecrolimus.
  • MROWIETZ U, GRAEBER M, BRAUTIGAM M et al.: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. Dermatol (1998) 139:992–996.
  • MEINGASSNER JG, FAHRNGRUBER H, BAVANDI A: Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. Invest. Dermatol. (2003) 121:77–80.
  • STUETZ A, GRASSBERGER M, MEINGASSNER JG: Pimecrolimus (Elidel, SDZ ASM 981)-preclinical pharmacologic profile and skin selectivity. Semin. Cutan. Med. Surg. (2001) 20:233–241.
  • MOORE HD, TYLDESLEY AM, MARTLAND A et al.: Pimecrolimus protects mice from developing T cell-induced inflammatory bowel disease without systemic immunosuppression, in contrast to tacrolimus or cyclosporin A. International Investigative Dermatology Miami Beach, FL, USA (2003) (Abstract).
  • RAPPERSBERGER K, KOMAR M, EBELIN ME et al: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.' Invest. Dermatol (2002) 119:876–887.
  • ••Watershed paper on oral pimecrolimus that also includes genomic profiling.
  • GRIFFITHS CE, DUBERTRET L, GOTTLIEB A: Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect. International Investigative Dermatology Miami Beach, FL, USA (2003) (Abstract).
  • HANIFIN JM, FLEMING C, KORMAN N, REITAMO S: Treatment with oral pimecrolimus significantly improves atopic dermatitis with a clear dose-response effect. International Investigative Dermatology Miami Beach, FL, USA (2003) (Abstract).
  • WOLFF K, CARO I, MURRELL D, ORTONNE J: Safety profile of oral pimecrolimus in atopic eczema and psoriasis: a pooled analysis from two dose-finding studies. International Investigative Dermatology Miami Beach, FL, USA (2003) (Abstract).
  • MOLLISON KW, FEY TA, GAUVIN DM et al.: Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Curt Pharm. Des. (1998) 4:367–379.
  • MOLLISON KW, FEY TA, GAUVIN DM et al.: A macrolactam inhibitor of T helper Type 1 and T helper Type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. j. Invest. Dermatol (1999) 112:729–738.
  • PETERSON LB, CRYAN JG, ROSA R et al.: A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. Transplantation (1998) 65:10–18.
  • GOULET MT, McALPINE SR, STARUCH MJ et al.: C32-0-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential. Bioorg. Med. Chem. Lett (1998) 8:2253–2258.
  • Expert Op/n. Investig. Drugs (2004) 13(2)
  • SEHGAL SN, BAKER H, VEZINA C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibia (Tokyo) (1975) 28:727–732.
  • VEZINA C, KUDELSKI A, SEHGAL SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) (1975) 28:721–726.
  • KAHAN BD: Sirolimus: a comprehensive review. Expert Opin. Pharinacother: (2001) 2:1903–1917.
  • MICHAEL J, GREENSTEIN S, SCHECHNER R et al.: Primary intestinal posttransplant T-cell lymphoma. Transplantation (2003) 75:2131–2132.
  • EISEN HJ, TUZCU EM, DORENT R et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl. J. Med (2003) 349:847–858.
  • DUMONT FJ: Everolimus. Novartis. CUIT. Opin. Livestig. Drugs (200 1) 2:1220-1234.
  • NASHAN B: Review of the proliferation inhibitor everolimus. Expert. Opin. Investig. Drugs (2002) 11:1845–1857.
  • •Interesting review.
  • MAJEWSKI M, KORECKA M, JOERGENSEN J et al: Immunosuppressive TOR kinase inhibitor everolimus (PAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation (2003) 75:1710-1717. Websites

Websites

  • http://www.cellgateinc.com Website of CellGate, Inc.
  • http://www.isotechnika.com Website of Isotechnica, Inc. Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.